Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. - Pfeifer, H; Wassmann, B; Bethge, W; Dengler, J; Bornhäuser, M; Stadler, M; Beelen, D; Vucinic, V; Burmeister, T; Stelljes, M; Faul, C; Dreger, P; et al. (Leukemia (08876924), 2013)